InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

InspireMD (Nasdaq: NSPR) will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026.

Rhea-AI Summary

InspireMD (Nasdaq: NSPR) will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and recent highlights.

A live audio webcast and archived recording will be available via the company Investors page, and participants are encouraged to register at least 15 minutes before the call.

Argus Mar 9 session

+0.61% close to close Open Argus

Details

News Market Reaction – NSPR

On Mar 9, the day this news came out, NSPR closed 0.61% above the previous close.

Data tracked by StockTitan Argus for the Mar 9 session.

Market Context

This announcement sets March 18, 2026 as the date for InspireMD’s Q4 and full-year 2025 results and ...

Analysis

This announcement sets March 18, 2026 as the date for InspireMD’s Q4 and full-year 2025 results and outlines an 8:30 a.m. ET call and webcast. Historically, the stock’s reactions to news have been mixed, with both gains and declines on clinical and corporate updates. Investors may focus on how upcoming financial metrics align with the company’s carotid stent commercialization progress and on any updates that build on prior clinical publications and institutional ownership disclosures.

Key Figures

Earnings release date: March 18, 2026 Conference call time: 8:30 a.m. ET

Earnings release date

March 18, 2026

Scheduled Q4 and full-year 2025 financial results release

Conference call time

8:30 a.m. ET

Time of earnings conference call and webcast

Historical Context

5 past events · Latest: Jan 20

5 events

1. Jan 20

   Inducement grant

   24h Move

   +1.3%

   Announcement of 36,118 restricted shares for a new non-executive employee.

2. Jan 12

   Clinical trial data

   24h Move

   -5.8%

   Publication of C-GUARDIANS pivotal trial in JACC showing low adverse events.

3. Nov 24

   External study results

   24h Move

   +1.6%

   CREST-2 data highlighting benefits of carotid artery stenting supporting CGuard platform.

4. Nov 21

   Inducement grants

   24h Move

   +13.5%

   Grants of 122,054 restricted shares to eight new non-executive employees.

5. Nov 19

   Conference participation

   24h Move

   -11.5%

   Participation announcement for the Piper Sandler 37th Annual Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

carotid stent

1 terms

carotid stent medical

"developer of the CGuard® Prime carotid stent system for the prevention of stroke"

A carotid stent is a small metal mesh tube placed inside a narrowed carotid artery in the neck to prop the vessel open and help restore normal blood flow to the brain, typically delivered through the blood vessels using a thin tube. For investors, it matters because regulatory approvals, clinical trial results, insurance coverage and surgical adoption drive device sales, pricing and legal risk—think of it like a scaffold that keeps a critical pipeline open, affecting demand and revenue for makers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD’s corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the start of the call.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.

Investor Contact:
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will InspireMD (NSPR) release Q4 and full year 2025 financial results?

InspireMD will release Q4 and full year 2025 results on March 18, 2026. According to InspireMD, the company plans to discuss results during a conference call and webcast at 8:30 a.m. Eastern Time that day.

What time is the InspireMD (NSPR) earnings call and webcast on March 18, 2026?

The earnings call and webcast begin at 8:30 a.m. Eastern Time on March 18, 2026. According to InspireMD, a live audio webcast and an archived recording will be available on the Investors page.

Where can investors access the InspireMD (NSPR) live webcast and archive?

Investors can access the live webcast and archived recording on InspireMD's Investors page at https://investors.inspiremd.com. According to InspireMD, the archive will be posted after the live audio webcast concludes.

Do I need to register to join the InspireMD (NSPR) March 18, 2026 call?

Interested participants are encouraged to register more than 15 minutes before the call start time. According to InspireMD, early registration helps ensure timely access to the live audio webcast and avoids connection delays.

What will InspireMD (NSPR) discuss on the March 18, 2026 conference call?

The company will discuss its fourth quarter and full year 2025 financial results and recent corporate highlights. According to InspireMD, management will review results and provide context during the conference call and webcast.